195 related articles for article (PubMed ID: 28039805)
1. Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α.
Berlec A; Perše M; Ravnikar M; Lunder M; Erman A; Cerar A; Štrukelj B
Int Immunopharmacol; 2017 Feb; 43():219-226. PubMed ID: 28039805
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor necrosis factor α therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis.
Petito V; Graziani C; Lopetuso LR; Fossati M; Battaglia A; Arena V; Scannone D; Quaranta G; Quagliariello A; Del Chierico F; Putignani L; Masucci L; Sanguinetti M; Sgambato A; Gasbarrini A; Scaldaferri F
World J Gastroenterol; 2019 Mar; 25(12):1465-1477. PubMed ID: 30948910
[TBL] [Abstract][Full Text] [Related]
3. Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice.
Nishitani Y; Tanoue T; Yamada K; Ishida T; Yoshida M; Azuma T; Mizuno M
Int Immunopharmacol; 2009 Nov; 9(12):1444-51. PubMed ID: 19733697
[TBL] [Abstract][Full Text] [Related]
4. Mucosal delivery of Lactococcus lactis carrying an anti-TNF scFv expression vector ameliorates experimental colitis in mice.
Chiabai MJ; Almeida JF; de Azevedo MGD; Fernandes SS; Pereira VB; de Castro RJA; Jerônimo MS; Sousa IG; de Souza Vianna LM; Miyoshi A; Bocca AL; Maranhão AQ; Brigido MM
BMC Biotechnol; 2019 Jun; 19(1):38. PubMed ID: 31238939
[TBL] [Abstract][Full Text] [Related]
5. Preventative delivery of IL-35 by Lactococcus lactis ameliorates DSS-induced colitis in mice.
Wang J; Tian M; Li W; Hao F
Appl Microbiol Biotechnol; 2019 Oct; 103(19):7931-7941. PubMed ID: 31456001
[TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C
Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Lactococcus lactis expressing porcine insulin-like growth factor I ameliorates DSS-induced colitis in mice.
Liu S; Li Y; Deng B; Xu Z
BMC Biotechnol; 2016 Mar; 16():25. PubMed ID: 26932768
[TBL] [Abstract][Full Text] [Related]
8. Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice.
Shigemori S; Watanabe T; Kudoh K; Ihara M; Nigar S; Yamamoto Y; Suda Y; Sato T; Kitazawa H; Shimosato T
Microb Cell Fact; 2015 Nov; 14():189. PubMed ID: 26608030
[TBL] [Abstract][Full Text] [Related]
9. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis.
Vandenbroucke K; de Haard H; Beirnaert E; Dreier T; Lauwereys M; Huyck L; Van Huysse J; Demetter P; Steidler L; Remaut E; Cuvelier C; Rottiers P
Mucosal Immunol; 2010 Jan; 3(1):49-56. PubMed ID: 19794409
[TBL] [Abstract][Full Text] [Related]
10. Oral Delivery of Mouse β-Defensin 14 (mBD14)-Producing
Tian H; Li J; Chen X; Ren Z; Pan X; Huang W; Bhatia M; Pan LL; Sun J
J Agric Food Chem; 2023 Apr; 71(13):5185-5194. PubMed ID: 36943701
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory effects of different strains of Lactococcus lactis in DSS-induced colitis.
Alves JL; Lemos L; Rodrigues NM; Pereira VB; Barros PAV; Canesso MCC; Guimarães MAF; Cara DC; Miyoshi A; Azevedo VA; Maioli TU; Gomes-Santos AC; Faria AMC
Braz J Microbiol; 2023 Jun; 54(2):1203-1215. PubMed ID: 36821043
[TBL] [Abstract][Full Text] [Related]
12. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
13. Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice.
Lopetuso LR; Petito V; Cufino V; Arena V; Stigliano E; Gerardi V; Gaetani E; Poscia A; Amato A; Cammarota G; Papa A; Sgambato A; Gasbarrini A; Scaldaferri F
Dig Liver Dis; 2013 Dec; 45(12):1017-21. PubMed ID: 23911613
[TBL] [Abstract][Full Text] [Related]
14. Brugia malayi cystatin therapeutically ameliorates dextran sulfate sodium-induced colitis in mice.
Khatri V; Amdare N; Tarnekar A; Goswami K; Reddy MV
J Dig Dis; 2015 Oct; 16(10):585-94. PubMed ID: 26358507
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of a novel probiotic strain, Lactococcus lactis ML2018, in colitis: in vivo and in vitro evidence.
Liu M; Zhang X; Hao Y; Ding J; Shen J; Xue Z; Qi W; Li Z; Song Y; Zhang T; Wang N
Food Funct; 2019 Feb; 10(2):1132-1145. PubMed ID: 30724927
[TBL] [Abstract][Full Text] [Related]
16. Unexpected effect of probiotics by Lactococcus lactis subsp. lactis against colitis induced by dextran sulfate sodium in mice.
Komaki S; Haque A; Miyazaki H; Matsumoto T; Nakamura S
J Infect Chemother; 2020 Jun; 26(6):549-553. PubMed ID: 32122783
[TBL] [Abstract][Full Text] [Related]
17. Le Carbone, a charcoal supplement, modulates DSS-induced acute colitis in mice through activation of AMPKα and downregulation of STAT3 and caspase 3 dependent apoptotic pathways.
Afrin MR; Arumugam S; Rahman MA; Karuppagounder V; Sreedhar R; Harima M; Suzuki H; Nakamura T; Miyashita S; Suzuki K; Ueno K; Watanabe K
Int Immunopharmacol; 2017 Feb; 43():70-78. PubMed ID: 27978459
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory properties of fermented soy milk with Lactococcus lactis subsp. lactis S-SU2 in murine macrophage RAW264.7 cells and DSS-induced IBD model mice.
Kawahara M; Nemoto M; Nakata T; Kondo S; Takahashi H; Kimura B; Kuda T
Int Immunopharmacol; 2015 Jun; 26(2):295-303. PubMed ID: 25887264
[TBL] [Abstract][Full Text] [Related]
19. Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis.
Zurita-Turk M; Del Carmen S; Santos AC; Pereira VB; Cara DC; Leclercq SY; de LeBlanc Ad; Azevedo V; Chatel JM; LeBlanc JG; Miyoshi A
BMC Biotechnol; 2014 Aug; 14():73. PubMed ID: 25106058
[TBL] [Abstract][Full Text] [Related]
20. Infliximab does not increase colonic cancer risk associated to murine chronic colitis.
Lopetuso LR; Petito V; Zinicola T; Graziani C; Gerardi V; Arena V; Caristo ME; Poscia A; Cammarota G; Papa A; Cufino V; Sgambato A; Gasbarrini A; Scaldaferri F
World J Gastroenterol; 2016 Nov; 22(44):9727-9733. PubMed ID: 27956796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
